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Background: Stereotactic body radiation therapy (SBRT) has emerged as an alternative treatment for patients with
early stage non-small cell lung cancer (NSCLC) or metastatic pulmonary tumors. However, for isolated lung metastasis
(ILM) of thoracic malignances after pulmonary lobectomy, reported outcomes of SBRT have been limited. This study
evaluates the role of SBRT in the treatment of such patients.
Methods: A retrospective search of the SBRT database was conducted in three hospitals. The parameters analyzed in
the treated patients were local control, progression-free survival (PFS), overall survival (OS), and the treatment-related
side-effects.
Results: In total, 23 patients with single ILM after pulmonary lobectomy treated with SBRT were identified and
the median follow-up time was 14 months (range: 6.0-47.0 months). Local recurrences were observed in two
patients during follow-up and the 1-year local control rate was 91.3%. Median PFS and OS for the studied cohort
were 10.0 months [95% confidence interval (CI) 5.1-14.9 months] and 21.0 months (95% CI 11.4-30.6 months),
respectively. Acute radiation pneumonitis (RP) of grade 2 or worse was observed in five (21.7%) and three (13.0%)
patients, respectively. Other treatment-related toxicities included chest wall pain in one patient (4.3%) and acute
esophagitis in two patients (8.7%). By Pearson correlation analysis, the planning target volume (PTV) volume and
the volume of the ipsilateral lung exposed to a minimum dose of 5 Gy (IpV5) were significantly related to the acute RP
of grade 2 or worse in present study (p < 0.05). The optimal thresholds of the PTV and IpV5 to predict RP of acute grade
2 or worse RP were 59 cm3 and 51% respectively, according to the receiver-operating characteristics curve analysis, with
sensitivity/specificity of 75.0%/80.0% and 62.5%/80.0%.
Conclusions: SBRT for post-lobectomy ILM was effective and well tolerated. The major reason for disease progression
was distant failure but not local recurrence. The PTV and IpV5 are potential predictors of acute RP of grade 2 or higher
and should be considered in treatment planning for such patients.
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Tumor lung metastasis is one of the most common onco-
logic problems, and affects a large percentage of patients
of cancer despite the histology of the primary tumor. In
most cases, widespread metastases are observed. But in
certain instances, lung metastasis may exist in isolation.
Resection of isolated lung metastasis (ILM) has tradition-
ally been practiced using methods, such as thoracotomy
and video-assisted thoracoscopic surgery (VATS) [1-5].
Such approaches have been proved to be effective, achiev-
ing a median survival of 35 months, and are associated
with generally acceptable morbidity and mortality rates
[6]. However, such pulmonary operations have been prac-
ticed in salvage treatments for colorectal cancer, breast
cancer and other types of tumors, and rarely for thoracic
tumor after pulmonary lobectomy.
Hypo-fractionated stereotactic body radiation therapy
(SBRT) can deliver high, biologically effective doses to
the tumors while minimizing the irradiation dose to the
surrounding tissues [7]. Over the decades, SBRT has
emerged as an alternative treatment for medically inop-
erable patients with early-stage non-small cell lung can-
cer (NSCLC), showing a 5-year survival rate of more
than 80% with limited morbidity [8-11]. Even among pa-
tients with multiple pulmonary metastases, SBRT has
been reported as a safe and effective strategy [12-14]. At
present, SBRT is recommended by the National Com-
prehensive Cancer Network (NCCN) panel as a salvage
treatment for patients with ILM [15].
For patients with ILM after pulmonary lobectomy, a
few treatment outcomes have been reported to date, in-
cluding for surgery and SBRT. Therefore, we retro-
spectively analyzed the clinical outcomes of patients at
our institutions with post-lobectomy ILM who were
treated with SBRT as a component of their overall treat-
ment regimen.Methods
Patients’ data
ILM in this study was defined as a circular shape 18 F-
fluorodeoxyglucose positron-emission tomography (FDG-
PET) or computed tomography (CT) imaging, without
any lobulated signs of original tumor within 3 years after
pneumonectomy. We reviewed the records of 268 con-
secutive patients treated with SBRT for thoracic tumors
between October 2009 and December 2013 at the West
China Hospital, Second People’s Hospital of Sichuan, and
Second Affiliated Hospital of Anhui Medical University.
Among these patients we identified 23 who had previ-
ously received radical resection of thoracic tumors (in-
cluding pulmonary lobectomy and systematic lymph
node dissection) and who subsequently underwent
SBRT to treat the ILM of the ipsilateral or contralaterallung. This retrospective study was carried out with the
approval of West China Hospital's ethics committee.SBRT treatment
The techniques for patient immobilization and treat-
ment planning have been described in detail in previous
reports [16,17]. In brief, all patients were simulated and
treated in stereotactic immobilization body frame with
an active breathing control (ABC) device. All CT im-
ages (3-mm thickness) of the patients were transferred
to and registered in the treatment planning system
(Pinnacle3, Philips Radiation Oncology Systems, Fitch-
burg, WI, USA). The gross tumor volume (GTV) was
contoured as the identifiable tumor on planning CT in
the lung window. The clinical target volume (CTV)
enclosed the GTV with a 5-mm margin in all direc-
tions. For the planning target volume (PTV), another
5-mm margin was added isotropically to the CTV. The
spinal cord, esophagus, bronchus and chest wall were
contoured as the organs at-risk (OARs).
Two groups of different doses were given to the PTV,
prescribed to the 80 or 90% isodose lines: for small and
peripherally located targets, radiation dose was pre-
scribed as 48 Gy/4 fractions or 50 Gy/5 fractions; for
targets close proximity to critical structures, radiation
dose was prescribed as 56 Gy/7 fractions (Table 1). All
fractions were scheduled as three times per week. The
dose-volume constraints used for OARs followed the
NCCN guidelines [15] and the recommendations from
the Radiation Therapy Oncology Group (RTOG) [18].
Plans were generated with five or seven coplanar beams
of 6-MV X-rays.Treatment assessment and follow-up
Evaluation of treatment response was carried out ac-
cording to Response Evaluation Criteria in Solid Tumors
(RECIST criteria) based on findings from either FDG-
PET or CT images [19]. Local recurrence was defined as
any re-enlargement of the target if complete response
(CR) had not been reached after SBRT or re-appearance
of the target if CR had been reached. Progression was
defined as a local recurrence or appearance of new le-
sions. Follow-up evaluations were started 4 weeks after
the date of the last SBRT treatment, and performed
every 2–3 months for the first 2 year and every 6 months
thereafter.
Toxicities were evaluated and graded according to
the National Cancer Institute Common Toxicity Cri-
teria Adverse Event version 3.0 (CTC AE v3.0) [20]. A
diagnosis of radiation pneumonitis (RP) was made
based on clinical symptoms (including cough, shortness
of breath and fever), and radiologic findings in the ab-
sence of any other likely cause.
Table 1 Treatment in present study (n = 23)
Stereotactic body radiation therapy
Irradiation dose delivered
12 Gy × 4 fractions three times per week 11 (47.8%)
10 Gy × 5 fractions three times per week 9 (39.1%)
8 Gy × 7 fractions three times per week 3 (13.0%)
Active breathing control 23 (100%)





Total lung (median) 2301.4
(range) 1983.4-2950.5
Contralateral lung (median) 1373.4
(range) 1255.8-1712.3




Concurrent chemotherapy 1 (4.3%)
Sequential chemotherapy 14 (60.9%)
Tyrosine kinase inhibitora 3 (13.0%)
None 5 (21.7%)
a: Erlotinib or Gefetinib.
Table 2 Basic and clinical characteristics of the patients in
present study (n = 23)
Characteristics Number of patients
(%)
Age (years)
Median (range) 58 (45–74)
Gender




Pathology of the primary tumor
Squamous-cell lung cancer 10 (43.5)
Non-squamous cell lung cancer 10 (43.5)
Sarcomatoid carcinoma 2 (8.7)
Small cell lung cancer 1 (4.3)
Surgical method
Right upper lung lobectomy 9 (39.1)
Right lower lung lobectomy 3 (13.0)
Left upper lung lobectomy 5 (21.7)
Left lower lung lobectomy 4 (17.4)
Left pneumonectomy 2 (8.7)
T staging after surgeryb
T1/T2/T3/T4 3 (13.0)/11 (47.8)/8
(34.8)/1(4.3)
N staging after surgeryb
N0/N1/N2 10 (43.5)/6 (26.1)/7
(30.4)




Time from surgery to lung metastasis
(months)
Median (range) 16.0 (4.0-75.0)
Sites of lung metastasis
Contralateral lung of the primary tumor 12 (52.2)
Ipsilateral lung of the primary tumor 11 (47.8)
Follow-up time since diagnosis of lung
metastasis (months)
Median (range) 14.0 (6.0-47.0)
a: Eastern Cooperative Oncology Group; b: staging system, 6th edition,
American Joint Committee on Cancer, 2002.
Xiong et al. BMC Cancer 2014, 14:719 Page 3 of 10
http://www.biomedcentral.com/1471-2407/14/719Statistical methods
Statistical analyses were performed using SPSS software
(version 17.0). The timing of recurrence or distant metas-
tasis was recorded as the time at which the first image
(FDG-PET or CT) showed abnormalities. Progression-free
survival (PFS) time was measured from the date of the last
SBRT to the date of the disease progression, and the over-
all survival (OS) time was considered from the last date of
treatment to the date of analysis or date of loss from
follow-up for patients alive. Patients without local recur-
rence or progression who discontinued the follow-up for
any reason were censored on the date on the last tumor
assessment.
The rates of PFS and OS curves were calculated using
Kaplan-Meier analysis. Spearman’s rank correlation ana-
lysis was applied to determine correlations between the
dose-volume histogram (DVH) -based parameters and the
incidence of RP. Receiver-operating characteristics (ROC)
curve analysis for each parameter was also applied to
select the most relevant threshold to predict RP for
grade 2 or higher. The optimal threshold for each
DVH-based parameter was defined as the point yielding
the minimal value for (1-sensitivity)2 + (1-specificity)2,according to the report from Akobeng [21]. A value of
p < 0.05 was considered to have statistical significance.
Results
The basic and clinical characteristics of the studied popula-
tion are summarized in Table 2. The median age of the
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were male and with Eastern Cooperative Oncology Group
(ECOG) performance status score 0–1 (21/23; 91.3%). Of
the 23 patients, 10 (43.5%) had squamous-cell lung cancer,
10 had non-squamous cell lung cancer and three (13%)
patients had, other pathological types respectively. Accord-
ing to our records, 9, 3, 5 and 4 patients had received
resection of right upper lobe, right lower lobe, left upper
lobe, and left lower lobe respectively. Two patients had
undergone left pneumonectomy. The pathologic stage
confirmed with surgery(Staging system, American Joint
Committee on Cancer, 6th edition) [22] in the present
study were 6 (26.1%) stage I, 9 (39.1%) stage II, and 8
(34.8%) stage III respectively. The ILMs of the contralateral
(12 patients) and ipsilateral (11 patients) lung were ob-
served. The median time from surgery to ILMs and follow-
up time was 16.0 months (range: 4.0-75.0 months, only 1
patient was diagnosed with ILM 75 months after pneu-
monectomy) and 14.0 months (range: 6.0-47.0 months),
respectively.Treatment
In the present study, 11 (47.8%), nine (39.1%) and three
(13.0%) patients had received the prescription dose of
48 Gy (4 fractions), 50 Gy (5 fractions) and 56 Gy (7
fractions), respectively (Table 1). The median PTV was
48.4 cm3 (range: 26.0-110.2 cm3). The median lung
volume was 2301.4 cm3 (range: 1983.4-2950.5 cm3). All
patients underwent ABC and cone-beam CT guidance
during treatment. Fourteen (60.9%) and 1(4.3%) pa-
tients received sequential and concurrent chemother-
apy respectively, as parts of the treatment strategies.
Three patients (13.0%) received tyrosine kinase inhibitorsFigure 1 Kaplan-Meier analysis of progression-free survival (a) and ovas the systematic treatment, and only five (21.7%) patients
had not received systematic therapy.
Local control and survival
Follow-up studies continued until December 2013, with
no patients lost to follow-up. Local recurrences were
observed in two patients during follow-up, and the 1-
year local control rate (LCR) was 91.3%. As Figure 1
shows, the median PFS and OS for the studied cohort
were 10.0 months [95% confidence interval (CI) 5.1-
14.9 months] and 21.0 months (95% CI 11.4-30.6 months),
respectively.
Figure 2 shows a patient with an ILM on the right
pulmonary lobe, whose primary tumor was sarcomatoid
carcinoma and who had received left pneumonectomy.
The irradiation dose delivered was 10 Gy per fraction
for five fractions. Figure 2 also shows a CR achieved
9 months after SBRT treatment (Figure 2c, d). Only light
patchy shadows near the chest wall were observed as
side effects of treatment.
Treatment-related toxicities
All patients were evaluated for treatment-related toxic-
ities (Table 3). The SBRT for ILM after pulmonary lob-
ectomy was judged to be tolerable. The most common
toxicity was cough (60.9%, 14 patients). Coughs of grade
2, 3, and 4 were recorded in four (17.4%), two (8.7%)
and one (4.3%) patients, respectively. Other toxicities in-
cluded shortness of breath (8.7%, two patients), acute
esophagitis (8.7%, two patients) and chest wall pain
(4.3%, one patient). No grade 5 toxicity was recorded.
Figure 3 shows a patient with ILM of small-cell lung
cancer on the right upper lobe after right lower lobec-
tomy. The prescription dose was 10 Gy per fraction forerall survival (b) in the present study.
Figure 2 Complete response after SBRT in the representative patient. (a: irradiation isodose curves of the SBRT plan 50 Gy in 5 fractions;
b: dose-volume histogram of the SBRT plan; c: CT image before SBRT; d: CT image 9 months after SBRT).
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mum dose of 20 Gy (V20) and V30 of total lungs was less
than 15 and 10% respectively. One month after SBRT,
the patient experienced severe cough and dyspnea; CT
scans showed a stable disease as the response to treat-
ment, and widespread, patchy shadows on both upperTable 3 The acute SBRTa-related toxicities in present
study (n = 23)
Toxicitiesb Toxicity grades, n (%)
Grade 0 Grade 1 Grade 2 Grade 3 Grade 4
Radiation pneumonitis
Cough 9 (39.1) 7 (30.4) 4 (17.4) 2 (8.7) 1 (4.3)c
Shortness of breath 21 (91.3) 0 1 (4.3) 0 1 (4.3)c
Other treatment-related toxicities
Chest wall pain 22 (95.7) 0 1 (4.3) 0 0
Acute esophagitis 21 (91.3) 0 2 (8.7) 0 0
a: stereotactic body radiation therapy; b : according to the Common Toxicity
Criteria for Adverse Events, version 3.0; c: same patient.lobes (grade 4 RP). After steroid therapy for 6 weeks, the
patient recovered.Correlations between lung parameters and incidence of
RP
Table 4 summarizes the correlations between the DVH-
based lung parameters and acute RP of grade 2or higher.
The incidence of acute RP of grade ≥2 was significantly
associated with the PTV (mean: 59.0vs.45.0 cm3, p =
0.039). Another possible predictive parameter was the V5
of the ipsilateral lungs (IpV5) (mean: 51.0 vs. 44.0%, p =
0.034). Other lung parameters did not significantly cor-
relate with the incidence of acute RP of grade 2 or
higher.
By ROC analysis, the areas under curve were 0.758
(p = 0.045) and 0.700 (p = 0.121) for PTV and IpV5, re-
spectively (Figure 4). Additionally, the optimal values to
predict acute RP of grade 2 or higher were 59 cm3 (for
PTV) with sensitivity of 75% and specificity of 80.0%
Figure 3 Representative patient who developed grade 4 radiation pneumonitis. (a: irradiation isodose curves of the SBRT plan 50 Gy in 5
fractions; b: dose-volume histogram of the SBRT plan, arrow pointing the curve of the total lung; c: CT image before SBRT; d: CT image one
month after SBRT).
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sensitivity/specificity of 62.5% and 80.0%, respectively.
Discussion
The treatment of cancer patients with ILM is a common
clinical problem. SBRT is an appealing treatment option,
but little is known about its use in the post-lobectomy
setting. Our initial experience of using hypo-fractionated
SBRT for ILM after pulmonary lobectomy is presented
here for the first time.
The 1-year LCR was 91.3% for all patients in the present
study, the median PFS and OS were 10.0 and 21.0 months,
respectively. Our data are consistent with those of other
reports on SBRT for metastatic lung cancer [23-25], espe-
cially the report from Norihisa et al. whose prescription
dose was 48–60 Gy/4-5 fractions and LCR 90.0% [25].
These clinical outcomes were comparable with those
achieved by surgical metastasectomy [6]. In 2009, Rusthoven
et al. reported a prospective multi-institutional phaseI/II trial of SBRT for metastatic lung tumor, and re-
ported actuarial LCRs at 1 and 2 years after SBRT of
100 and 96%, respectively. After a median follow-up of
15.4 months, a median survival of 19 months was
achieved using a prescription dose of 48–60 Gy in three
fractions [26]. Our data also confirmed that the main
pattern of failure after SBRT was distant metastasis, as
was concluded in a systematic review by Chi et al. [27].
A few studies have evaluated the outcomes of SBRT
among patients after pneumonectomy [28-30]. Authors
from the VU University Medical Center in the Netherlands
reported on 15 patients with a second primary lung cancer
who received SBRT after pneumonectomy in 2009 [28].
After a median follow-up time of 16.5 months, no local
failures were observed and the 1-year actuarial disease-free
survival rate was 92%. In 2013, the same investigatorsy up-
dated their data and compared the outcomes between
SBRT, hypo-fractionated radiotherapy, and conventional
radiotherapy among such patients [29]. In this paper, they
Table 4 Correlations between the DVHa-based parameters and acute grade ≥2 RPb in present study (n = 23)
Grade ≥2 RIP (n = 8) Grade 0–1 RIP (n = 15)
p valuemean ± SD mean ± SD
Total Lungs
V5 (%)
c 36.0 ± 6.0 35.0 ± 4.0 0.141
V10 (%)
c 16.0 ± 4.0 14.0 ± 2.0 0.125
V20 (%)
c 4.8 ± 2.0 4.4 ± 1.2 0.696
V30 (%)
c 2.0 ± 1.0 2.0 ± 1.0 0.990
MLD (Gy) d 3.8 ± 1.6 3.7 ± 1.3 0.077
Contralateral lungs
V5 (%) 26.0 ± 7.0 25.0 ± 9.0 0.421
V10 (%) 18.0 ± 7.0 16.0 ± 9.0 0.277
V20 (%) 3.2 ± 1.1 2.4 ± 0.9 0.210
V30 (%) 1.6 ± 0.5 1.6 ± 0.6 0.992
MLD (Gy) 2.8 ± 0.6 2.6 ± 0.2 0.483
Ipsilateral lungs
V5 (%) 51.0 ± 9.1 44.0 ± 4.0 0.034
V10 (%) 22.0 ± 6.0 19.0 ± 4.0 0.273
V20 (%) 6.0 ± 2.8 5.2 ± 2.2 0.454
V30 (%) 2.6 ± 1.0 2.8 ± 1.1 0.824
MLD (Gy) 5.9 ± 1.3 5.7 ± 1.1 0.290
PTV volume (cm3) 59.0 ± 9.6 45.0 ± 9.9 0.039
a: dose-volume histogram; b: radiation pneumonitis; c: the percentage of the lung volume that received more than 5, 10, 20 and 30 Gy irradiation dose,
respectively; d: mean lung dose.
Figure 4 Receiver operating characteristics (ROC) curve analysis in present study. (a: for PTV volume and b: for V5 of the ipsilateral lung).
Xiong et al. BMC Cancer 2014, 14:719 Page 7 of 10
http://www.biomedcentral.com/1471-2407/14/719
Table 5 ROCa curve analysis for DVHb-based parameters
related to acute grade ≥2 RPc in present study
Parameters Optimal threshold
Value Sensitivity Specificity
PTV volume (cm3) 59 75.0% 80.0%
Ipsilateral lung V5
d (%) 51 62.5% 80.0%
a: receiver operating characteristic; b: dose-volume histogram; c: radiation
pneumonitis; d: the percentage of the ipsilateral lung volume that received
more than 5 Gy irradiation dose.
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Thompson et al. identified 13 patients with newly identi-
fied lung malignancy after surgery from 406 patients who
received SBRT [30]. The doses delivered were 60 Gy/3
fractions (n = 1), 54 Gy/3 fractions (n = 1), 48 Gy/4 frac-
tions (n = 7), 60 Gy/8 fractions (n = 2), and 50 Gy/10 frac-
tions (n = 3). The Median survival was 29 months, and no
local failures were observed. In our cohort, the targets were
metastatic tumors; thus, even though the local control rate
was similar to that the reported in the aforementioned
studies discussed above, the OS (median 21 months)
among our patients was shorter than in those patients
with newly diagnosed lung cancer.
The SBRT treatment was well tolerated in our patient
population. The most common toxicity was cough
(60.9%), and acute RP of grade 3 or worse was observed in
three patients (13.0%). Other treatment-related toxicities
included dyspnea, chest wall pain, and acute esophagitis.
These findings are consistent with the reports evaluating
SBRT in newly identified lung cancer after pneumonec-
tomy [28,30] and in medically inoperable or operable
NSCLC [26,31-37]. In the post-pneumonectomy settings,
Haasbeek et al. reported that only two2 patients experi-
enced toxicity of grade 3 or higher toxicity [28]. In a re-
port by Thompson et al., two2 patients in a 13-patient
cohort had grade 3 RP [30]. For medically inoperable or
operable NSCLC, in the RTOG trial 0236, with a prescrip-
tion dose of 54 Gy in three fractions, treatment-related
grade 3 and 4 toxicities of pulmonary or upper respiratory
tract were observed in 14.5 and 1.8% of patients, respect-
ively [31]. In a phase II study of SBRT, Baumann et al. re-
ported that grade 3 pulmonary toxicities were seen in 11.8
and 12.5% of patients in the cardio-vascular disease group
and chronic obstructive pulmonary disease group, respect-
ively [32]. In a study from Japan (JCOG 0403), Nagata
et al. reported grade 3 toxicity in 6.2% of their patients
who received SBRT treatment [33]. For metastatic lung
cancer, Rusthoven et al. reported that grade 2 RP occurred
in only one patient (2.6%) in their multi-institutional
phase I/II trial [26]. The investigators suggested that the
low rate of pneumonitis observed might have contributed
to the dose constraint used (V15 < 35%) in their patient
population. However this needs to be confirmed in a lar-
ger cohort of patients because in our study, one patientdeveloped grade 4 RP, and the V15 was less than 17% ac-
cording to the DVH analysis.
Several studies have evaluated the potential value of
the DVH-based lung parameters in predicting acute
“symptomatic” RP after SBRT [34-38]. The RP rates
were reported within a range of 9.4% to 28.0%, and the
possible predictive factors for RP differed among these
studies. In 2007, Yamashita et al. reported that 29% of
their patients had developed grade 2 or worse RP after
SBRT (48 Gy in four fractions), and that the conformity
index was the only factor associated with incidence of
RP [34]. Ricardi et al. observed a good correlation be-
tween mean lung dose (MLD) and grade 2–3 pulmonary
toxicity (p = 0.008, odds ratio 1.5) in a 60-patients cohort
after SBRT of 15 Gy per fraction × 3 fractions [35].
Moreover, reports by Borst et al., Guckenberger et al.
and Barriger et al. indicated that MLD (ipsilateral or
total lung) was correlated with incidences of symptom-
atic RP after pulmonary SBRT [36-38]. Onestudy indi-
cated that V5 of total lung >37% and V5 of contralateral
lung > 26% were suitable predictors of pneumonitis in a
cohort of patients treated with SBRT [39]. Additionally,
Guckenberger et al. reported that the V2.5-V50 were cor-
related with incidences of RP with a continuous decrease
of the goodness of fit for higher doses [37]. In a Japanese
study, Matsuo et al. concluded that the symptomatic RP
rate was significantly lower in the group with PTV <
37.7 mL compared with the group with larger PTV (11.1
vs. 34.5%, p = 0.02) [40]. In the present study, we also
identified two factors that might significantly be associ-
ated with RP of grade 3 or worse after SBRT in the
post-lobectomy situation: PTV and IpV5. Like other
parameters already mentioned, the value of these two
factors as the thresholds in SBRT for ILM warrants
further clinical investigations.
To the best of our knowledge, there is little information
regarding the correlation between various DVH-based fac-
tors and lung toxicity in radiotherapy among patients after
pulmonary lobectomy. Uno et al. reported that higher in
V13/20 and MLD values could be a surrogate for RP in
NSCLC patients after lobectomy [41]. While the treat-
ment was concurrent chemo-radiotherapy for recurrent
NSCLC, these parameters could not be easily followed in
an SBRT setting.
Some limitations of the present study justify mention.
First, this analysis was retrospective and the number of
patients evaluated was limited, thus leading to a bias of
selection. Second, being a multicenter study, there was
no central data review, and the determination of RP can
be subjective and challenging. Third, there is an obvious
difference between the RTOG system, CTC AE v2.0, and
CTC AE v3.0 regarding steroid use for RP. Tucker et al.
reported 442 patients who received definitive radiother-
apy using these three toxicity grading systems: RP of
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tients according to RTOG, CTC AE v2.0 and CTC AE
v3.0, respectively [42]. Therefore, attention should be
paid to the toxicity grading systems when interpreting
the results discussed herein.Conclusions
In conclusion, our results indicate that SBRT is a prom-
ising tool for the salvage treatment of ILM in patients
who had previously received pulmonary lobectomy. PTV
and IpV5 are possible predictive factors for the develop-
ment of symptomatic RP. Prospective studies are needed
to verify these findings.
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